Abstract
Few diseases fluctuate as much as multiple sclerosis. This makes not only treatment but assessment difficult. Nevertheless, evidence from clinical, imaging, and cerebrospinal fluid studies1support Professor Compston's findings and conclusions that highdose intravenously administered methylprednisolone shortens the course of acute exacerbations and relieves spasticity in chronic cases. Professor Compston states that this represents only a modest advance in the treatment of multiple sclerosis. A little is a lot where there is little else. Reference
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
